beta

LPCN

Lipocine Inc

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

lipocine inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products. the company develops drugs based on hydroance, a drug delivery technology. it primarily focuses on developing oral versions of several hormones for use in men and women health. the company’s lipid-based technology platform offers non-invasive delivery solutions for small polar organics and macromolecules. it also offers custom drugs for pharmaceutical/biotechnology companies. lipocine inc. was founded in 1997 and is headquartered in salt lake city, utah.

Market Cap: 19 Million

Primary Exchange: NASDAQ

Website: https://www.lipocine.com/

Shares Outstanding: 5.32 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 0.4717280388431552

Sector: Manufacturing

Industry: Pharmaceutical Preparation Manufacturing

Ethical Flags

Longest drawdown: 2166 trading days

From: 2015-09-08 To: 2023-05-11

Lowest Point:

Antares Pharma: What The Market Is Missing

via: SeekingAlpha at 2019-06-11 01:18:27:000

As the chart below illustrates, Antares Pharma ( ATRS ) stock has been down and under pressure since the FDA approval of Clarus Therapeutics' TRT drug Jatenzo on March 28, which gives an indication of lower investor sentiment and expectations. (Courtesy StockCharts.com) After reaching an i… read more...

Antares Pharma: What The Market Is Missing

via: SeekingAlpha at 2019-06-11 01:18:27:000

As the chart below illustrates, Antares Pharma ( ATRS ) stock has been down and under pressure since the FDA approval of Clarus Therapeutics' TRT drug Jatenzo on March 28, which gives an indication of lower investor sentiment and expectations. (Courtesy StockCharts.com) After reaching an i… read more...

Antares Pharma: What The Market Is Missing

via: SeekingAlpha at 2019-06-11 01:18:27:000

As the chart below illustrates, Antares Pharma ( ATRS ) stock has been down and under pressure since the FDA approval of Clarus Therapeutics' TRT drug Jatenzo on March 28, which gives an indication of lower investor sentiment and expectations. (Courtesy StockCharts.com) After reaching an i… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud